Latest Safety News

Page 5 of 252
Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.
Ada Torres
Ada Torres
30 Oct 2026
ClearVue Technologies has converted its Canva project into a binding subcontract and secured certifications that broaden the market for its solar glass. But the ASX-listed company ended Q1 FY27 with A$2.281 million in cash, A$2.666 million of quarterly operating outflows and estimated funding for just 1.3 quarters.
Victor Sage
Victor Sage
30 Oct 2026
Syntara has reported statistically significant exploratory results for its Parkinson’s-related drug SNT-4728, while advancing blood-cancer and scar studies. The quarter also brought A$4.7 million in R&D funding, but the liquidation of a former buyer threatens a facility relocation and recovery of about A$0.6 million.
Ada Torres
Ada Torres
30 Oct 2026
Kingsgate’s cash balance climbed to A$108.9 million despite a difficult September quarter at Chatree, where a 47-day mill shutdown, heavy rainfall and geotechnical constraints cut gold production. The company is relying on a stronger second half of FY27, insurance proceeds and longer-term growth at Nueva Esperanza to offset the near-term disruption.
Maxwell Dee
Maxwell Dee
30 Oct 2026
H2G says its first PowerSafe stackable sodium-ion battery shipments have sold out, with products now available across Australia’s three eastern states. The company reported a sodium-ion sales pipeline above $4 million, alongside a $10 million-plus supercapacitor pipeline and quarter-end cash of $881,000.
Maxwell Dee
Maxwell Dee
30 Oct 2026
ABx Group has completed its $2 million underwritten share purchase plan, with shareholders subscribing for $1.1 million and the remaining shortfall placed through the underwriter. The raising delivers fresh capital but also adds 95.2 million shares and 238.1 million options across the transaction.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Arafura Rare Earths has moved its Nolans rare earths project from financing decision to early construction, with A$700 million of procurement scope advanced during the September quarter. The company ended the period with A$885 million in cash and term deposits, while major debt and equity funding arrangements remain subject to completion conditions.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026
Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.
Victor Sage
Victor Sage
30 Oct 2026
PDI Gold generated US$282.9 million in September-quarter revenue and ended the period with US$405 million in cash and bullion, despite weaker production at Nampala. The company maintained its 2026 output guidance as Kiniéro continued to carry the operating platform and Bankan moved closer to execution.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.
Victor Sage
Victor Sage
30 Oct 2026
Aura has reported 25% year-on-year exit ARR growth and positive underlying free cash flow in its first quarter after completing the Qoria acquisition. The company reaffirmed its 2026 targets, but the result remains pro forma and unaudited as integration work begins.
Sophie Babbage
Sophie Babbage
30 Oct 2026

Browse the archive

Full archive